Bank of Montreal vs Medpace Holdings Inc — how do they compare? Bank of Montreal trades at $182.65 (market cap $126.83B), while Medpace Holdings Inc trades at $600.5 (market cap $16.90B). The key difference: Bank of Montreal is far larger — about 7.5× Medpace Holdings Inc's market cap, and Bank of Montreal pays a 2.69% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| BMO | MEDP | |
|---|---|---|
Market Cap | $126.83B | $16.90B |
Sector | Financials | Technology |
52-Week High | $183.65 | $620.59 |
52-Week Low | $112.54 | $393.42 |
Dividend Yield | 2.69% | — |
Enterprise Value | — | $16.52B |
Signals from Pluang's Aura AI — not financial advice
BMO trades at $181.91, up 0.2% today, with a bullish technical signal from moving averages and support near $181. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.68 exceeding the $2.54 estimate. Revenue grew to $36.10B in 2025, and net income margin improved to 24.12%. Recent news includes the sale of Moneris for $1.44B and the launch of new ETNs with REX Shares.
Outlook is supported by consistent earnings performance and strategic initiatives, but risks include interest rate sensitivity and macroeconomic pressures. Analysts are divided with a Hold consensus, reflecting balanced optimism and caution. The stock's valuation at a P/E of 19.41 appears reasonable given profitability trends.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →